Cargando…
Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
BACKGROUND: At present, immune checkpoint inhibitors, such as pembrolizumab, are widely used in the therapy of advanced non-resectable melanoma, as they induce more durable responses than other available treatments. However, the overall response rate does not exceed 50% and, considering the high cos...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6781362/ https://www.ncbi.nlm.nih.gov/pubmed/31590677 http://dx.doi.org/10.1186/s12967-019-2081-2 |